Your browser doesn't support javascript.
loading
A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6.
Shen, Yudao; Li, Fengling; Szewczyk, Magdalena M; Halabelian, Levon; Chau, Irene; Eram, Mohammad S; Dela Seña, Carlo; Park, Kwang-Su; Meng, Fanye; Chen, He; Zeng, Hong; Dong, Aiping; Wu, Hong; Trush, Viacheslav V; McLeod, David; Zepeda-Velázquez, Carlos A; Campbell, Robert M; Mader, Mary M; Watson, Brian M; Schapira, Matthieu; Arrowsmith, Cheryl H; Al-Awar, Rima; Barsyte-Lovejoy, Dalia; Kaniskan, H Ümit; Brown, Peter J; Vedadi, Masoud; Jin, Jian.
Afiliación
  • Shen Y; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Li F; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Szewczyk MM; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Halabelian L; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Chau I; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Eram MS; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Dela Seña C; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Park KS; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Meng F; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Chen H; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Zeng H; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Dong A; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Wu H; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Trush VV; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • McLeod D; Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
  • Zepeda-Velázquez CA; Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
  • Campbell RM; Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46225, United States.
  • Mader MM; Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46225, United States.
  • Watson BM; Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46225, United States.
  • Schapira M; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Arrowsmith CH; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Al-Awar R; Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Barsyte-Lovejoy D; Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
  • Kaniskan HÜ; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Brown PJ; Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
  • Vedadi M; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Jin J; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
J Med Chem ; 64(7): 3697-3706, 2021 04 08.
Article en En | MEDLINE | ID: mdl-33591753
ABSTRACT
Protein arginine methyltransferase 6 (PRMT6) catalyzes monomethylation and asymmetric dimethylation of arginine residues in various proteins, plays important roles in biological processes, and is associated with multiple cancers. To date, a highly selective PRMT6 inhibitor has not been reported. Here we report the discovery and characterization of a first-in-class, highly selective allosteric inhibitor of PRMT6, (R)-2 (SGC6870). (R)-2 is a potent PRMT6 inhibitor (IC50 = 77 ± 6 nM) with outstanding selectivity for PRMT6 over a broad panel of other methyltransferases and nonepigenetic targets. Notably, the crystal structure of the PRMT6-(R)-2 complex and kinetic studies revealed (R)-2 binds a unique, induced allosteric pocket. Additionally, (R)-2 engages PRMT6 and potently inhibits its methyltransferase activity in cells. Moreover, (R)-2's enantiomer, (S)-2 (SGC6870N), is inactive against PRMT6 and can be utilized as a negative control. Collectively, (R)-2 is a well-characterized PRMT6 chemical probe and a valuable tool for further investigating PRMT6 functions in health and disease.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteína-Arginina N-Metiltransferasas / Benzodiazepinonas / Proteínas Nucleares / Inhibidores Enzimáticos Límite: Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteína-Arginina N-Metiltransferasas / Benzodiazepinonas / Proteínas Nucleares / Inhibidores Enzimáticos Límite: Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos